Patient Square Capital LP — 13F Holdings & Portfolio
CIK 1819257 · latest 13F-HR filed 2026-11-10
Patient Square Capital LP manages $626.7M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are ROIV (45.00%), RVMD (6.42%), UTHR (5.42%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 6 new positions and exited 6; 5 existing positions rose in reported value and 10 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-10
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
5 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 80.6%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated May 26, 2026.
SUITE 100
MENLO PARK, CA 94025
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| DRAYER-GREENWALT, CAROLYN, JOY Control | CHIEF COMPLIANCE OFFICER AND MANAGING DIRECTOR since May 2022 | Less than 5% | Individual |
| FLISS, ADAM, MARK Control | FOUNDING PARTNER; HEAD OF STRATEGY, CAPITAL, LEGAL, AND GOVERNMENT AFFAIRS since Oct 2020 | Less than 5% | Individual |
| MOMTAZEE, JAMES, CAMERON Control | MANAGING PARTNER since Aug 2020 | Less than 5% | Individual |
| PATIENT SQUARE CAPITAL HOLDINGS, LLC Control | GENERAL PARTNER since Feb 2021 | Less than 5% | Domestic Entity |
| PATIENT SQUARE PARTNER HOLDINGS, LP Control | LIMITED PARTNER since Feb 2021 | 75% or more | Domestic Entity |
| Wade, Christopher Control | CHIEF FINANCIAL OFFICER AND PARTNER since Jan 2026 | Less than 5% | Individual |
| MOMTAZEE, JAMES, CAMERON Control Indirect owner via PATIENT SQUARE PARTNER HOLDINGS, LP | LIMITED PARTNER since Feb 2021 | 50–75% | Individual |
| MOMTAZEE, JAMES, CAMERON Control Indirect owner via PATIENT SQUARE CAPITAL HOLDINGS, LLC | MANAGING MEMBER since Aug 2020 | 75% or more | Individual |
| PATIENT SQUARE CAPITAL HOLDINGS, LLC Control Indirect owner via PATIENT SQUARE PARTNER HOLDINGS, LP | GENERAL PARTNER since Feb 2021 | General partner, trustee or manager | Domestic Entity |
Ownership & leadership changes · 7 filings with changes since Feb 10, 2021
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedMOMTAZEE, JAMES, CAMERON · indirect via PATIENT SQUARE PARTNER HOLDINGS, LP: ownership 25–50% → 50–75%
- No longer listedWHELAN, MATTHEW, MICHAEL · CHIEF FINANCIAL OFFICER AND PARTNER · Less than 5% · control person · listed since Oct 2023
- AddedWade, Christopher · CHIEF FINANCIAL OFFICER AND PARTNER · Less than 5% · control person
- ChangedDRAYER-GREENWALT, CAROLYN, JOY · title CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER AND MANAGING DIRECTOR
- ChangedFLISS, ADAM, MARK · title GENERAL COUNSEL AND FOUNDING PARTNER → FOUNDING PARTNER; HEAD OF STRATEGY, CAPITAL, LEGAL, AND GOVERNMENT AFFAIRS
- AddedMOMTAZEE, JAMES, CAMERON · LIMITED PARTNER · 25–50% · indirect via PATIENT SQUARE PARTNER HOLDINGS, LP · control person
- AddedPATIENT SQUARE CAPITAL HOLDINGS, LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via PATIENT SQUARE PARTNER HOLDINGS, LP · control person
- AddedPATIENT SQUARE PARTNER HOLDINGS, LP · LIMITED PARTNER · 75% or more · control person
- ChangedMOMTAZEE, JAMES, CAMERON · title MANAGING PARTNER AND LIMITED PARTNER → MANAGING PARTNER; ownership 75% or more → Less than 5%
- No longer listedWALKER, MARIA, CONCEPCION · CHIEF FINANCIAL OFFICER AND FOUNDING PARTNER · Less than 5% · control person · listed since Feb 2021
- AddedWHELAN, MATTHEW, MICHAEL · CHIEF FINANCIAL OFFICER AND PARTNER · Less than 5% · control person
- ChangedDRAYER-GREENWALT, CAROLYN, JOY · now a control person
- AddedDRAYER-GREENWALT, CAROLYN, JOY · CHIEF COMPLIANCE OFFICER · Less than 5%
- ChangedFLISS, ADAM, MARK · title CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL AND FOUNDING PARTNER → GENERAL COUNSEL AND FOUNDING PARTNER
- ChangedMOMTAZEE, JAMES, CAMERON · title MANAGING PARTNER → MANAGING PARTNER AND LIMITED PARTNER
- ListedFLISS, ADAM, MARK · CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL AND FOUNDING PARTNER · Less than 5% · control person
- ListedMOMTAZEE, JAMES, CAMERON · MANAGING PARTNER · 75% or more · control person
- ListedMOMTAZEE, JAMES, CAMERON · MANAGING MEMBER · 75% or more · indirect via PATIENT SQUARE CAPITAL HOLDINGS, LLC · control person
- ListedPATIENT SQUARE CAPITAL HOLDINGS, LLC · GENERAL PARTNER · Less than 5% · control person
- ListedWALKER, MARIA, CONCEPCION · CHIEF FINANCIAL OFFICER AND FOUNDING PARTNER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- UNITED THERAPEUTICS CORP DEL$13.9M +68.9%
- ARGENX SE$5.5M +25.8%
- BELITE BIO INC$5.4M +32.0%
- KYMERA THERAPEUTICS INC$3.9M +72.4%
- PHARVARIS N V$2.4M +10.5%
Top Trims
- BEONE MEDICINES LTD-$13.4M -52.2%
- REVOLUTION MEDICINES INC-$11.5M -22.2%
- MIRUM PHARMACEUTICALS INC-$10.5M -34.4%
- COGENT BIOSCIENCES INC-$4.9M -29.5%
- ABIVAX SA-$3.5M -12.6%
New Positions
- ZAI LAB LTD$15.6M
- DEFINIUM THERAPEUTICS INC$14.7M
- COMPASS PATHWAYS PLC$13.1M
- VAXCYTE INC$9.4M
- ZENTALIS PHARMACEUTICALS INC$5.6M
Exited Positions
- XENON PHARMACEUTICALS INC$13.3M
- DIANTHUS THERAPEUTICS INC$10.5M
- EYEPOINT INC$10.3M
- ARCUTIS BIOTHERAPEUTICS INC$9.7M
- C4 THERAPEUTICS INC$7.5M
Patient Square Capital LP Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $282.0M | 45.00% | 7,710,928 | SH |
| 2 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $40.2M | 6.42% | 196,000 | SH |
| 3 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $34.0M | 5.42% | 62,677 | SH |
| 4 | ARGENX SE | ARGX | 04016X101 | $26.8M | 4.28% | 28,000 | SH |
| 5 | PHARVARIS N V | PHVS | N69605108 | $25.7M | 4.09% | 808,644 | SH |
| 6 | ABIVAX SA | ABVX | 00370M103 | $24.1M | 3.84% | 243,000 | SH |
| 7 | BELITE BIO INC | BLTE | 07782B104 | $22.4M | 3.57% | 131,700 | SH |
| 8 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $20.0M | 3.19% | 234,000 | SH |
| 9 | ZAI LAB LTD | ZLAB | 98887Q104 | $15.6M | 2.49% | 591,510 | SH |
| 10 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $14.7M | 2.34% | 385,000 | SH |
| 11 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $13.1M | 2.10% | 1,056,269 | SH |
| 12 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $13.0M | 2.07% | 1,105,606 | SH |
| 13 | BEONE MEDICINES LTD | ONC | 07725L102 | $12.3M | 1.96% | 33,500 | SH |
| 14 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $11.6M | 1.85% | 361,927 | SH |
| 15 | ARCUS BIOSCIENCES INC | RCUS | 03969F109 | $10.6M | 1.69% | 410,000 | SH |
| 16 | BIONTECH SE | BNTX | 09075V102 | $10.4M | 1.65% | 105,421 | SH |
| 17 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $9.7M | 1.55% | 212,500 | SH |
| 18 | VAXCYTE INC | PCVX | 92243G108 | $9.4M | 1.51% | 166,000 | SH |
| 19 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $9.4M | 1.50% | 84,000 | SH |
| 20 | ALLOGENE THERAPEUTICS INC | ALLO | 019770106 | $7.3M | 1.16% | 4,550,000 | SH |
| 21 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $5.6M | 0.89% | 2,007,485 | SH |
| 22 | INVENTIVA SA | IVA | 46124U107 | $4.5M | 0.72% | 1,221,225 | SH |
| 23 | HARROW INC | HROW | 415858109 | $4.5M | 0.71% | 145,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-10 | $626.7M | 23 | 0001819257-26-000007 |
| 2026-06-30 | 2026-08-12 | $645.5M | 23 | 0001819257-26-000005 |
| 2026-03-31 | 2026-05-15 | $563.6M | 29 | 0001819257-26-000003 |
| 2025-12-31 | 2026-02-12 | $467.1M | 28 | 0001819257-26-000002 |
| 2025-09-30 | 2025-11-10 | $373.9M | 24 | 0001819257-25-000002 |
MENLO PARK, CA 94025